medigraphic.com
ISSN 1561-3054 (Electronic)

2019, Number 1

<< Back Next >>

Rev Cubana Med Trop 2019; 71 (1)

Evaluation of the larvicidal efficacy of Rapidall NP3 (Bacillus thuringiensis) against Aedes aegypti (Linnaeus) (Diptera: Culicidae) in laboratory conditions

González RA, Companioni IA, Menéndez DZ, Anaya MJ, García GI, Lorenzo BCM, Castañet CE, Gato AR

Language: Spanish
References: 19
Page: 1-8
PDF size: 163.41 Kb.


ABSTRACT

Mosquitoes are vectors of human diseases such as dengue, zika and chikungunya. Biological control is a viable alternative to be taken into account in control programs. Bacillus thuringiensis is the microorganism most commonly used in public health. Its effectiveness as a larvicide against culicides depends to a great extent to the production process. The objectives of the study were to evaluate and compare the larvicidal efficacy against Aedes aegypti of the Rapidall NP3 powder formulation with Bactivec®, a liquid formulation used in Cuba. Laboratory bioassays were conducted to determine efficacy following WHO protocols. Larvae were exposed to the concentrations recommended by Rapidall NP3 and Bactivec® manufacturers. The water in the containers used in the study was replaced once a week: half, whole and no replacement. At 24 hours mortality was estimated and statistically analysis were done by one-way ANOVA. When significant differences were found, post-hoc analysis was performed with Tukey's test. Rapidall NP3 caused 100% larval mortality for 11 weeks, regardless of the water replacement proportion, whereas Bactivec® caused 100 % mortality for only 6 weeks after the start of the experiment. When compared with Bactivec®, biolarvicide Rapidall NP3 displayed better efficacy and more prolonged residual activity. We therefore recommend its field evaluation for larval control of containers constituting habitual breeding sites which cannot be physically eliminated.


REFERENCES

  1. WHO. Integrating neglected tropical diseases into global health and development: fourth WHO report on neglected tropical diseases. Geneva: World Health Organization; 2017.

  2. Mittal PK. Biolarvicides in vector control: challenges and prospects. J Vector Borne Dis. 2003;40(1-2):20-32.

  3. Ben Dov E. Bacillus thuringiensis subsp. israelensis and its dipteran-specific toxins. Toxins (Basel). 2014;64(6):1222-43.

  4. Stevens M, Akhurst R, Clifton M, Hughes P. Factors affecting the toxicity of Bacillus thuringiensis var. israelensis and Bacillus sphaericus to fourth instar larvae of Chironomus tepperi (Diptera: Chironomidae). J Invertebr Pathol. 2004;83(3):104-10.

  5. Cao C, Sun L, Wen R, Li X, Wu H, Wang Z. Toxicity and affecting factors of Bacillus thuringiensis var. israelensis on Chironomus kiiensis larvae. J Insect Sci. 2012;12(126):1-8.

  6. Corbillon CO, Gonzalez A, Menendez Z, Companioni A, Bruzon RY, Diaz M, et al. Influencia de factores bióticos sobre la eficacia de Bacillus thuringiensis var. israelensis contra Aedes aegypti (Diptera: Culicidae). Rev Cubana Med Trop. 2012;64(3):235-43.

  7. Aguilera L, González M, Marquetti M, Capín J, Fustes C. Incidencia de Aedes (S) aegypti y otros culícidos en el municipio Playa, Ciudad de La Habana. Rev Cubana Med Trop. 2000;52(3):174-9.

  8. Marquetti M, Fuster C, Martín I. Distribución espacial y temporal de los sitios de cría de Aedes albopictus y Aedes aegypti (Diptera:culicidae) en Pinar del Río, Cuba. Rev Biomed. 2014;25:54-67.

  9. WHO. Guidelines for laboratory and field testing of mosquito larvicides. Geneva, Switzerland: World Health Organization; 2005. WHO/CDS/WHOPES/GCDPP/2005.3.

  10. Tamilselvan S, Jambulingam P, Manoharan V, Shanmugasundaram R, Vivekanandan G, Manonmani AM. Fly ash based Bacillus thuringiensis var. israelensis formulation for use against Culex quinquefasciatus, the vector of filariasis in natural ecosystems. J Vector Borne Dis. 2015;52:193-200.

  11. Cetin H, Oz E, Yanikoglu A, Cilek JE. Operational Evaluation Of Vectomax® WSP (Bacillus thuringiensis Subsp. israelensis + Bacillus sphaericus) Against Larval Culex pipiens in Septic Tanks. J Am Mosq Control Assoc. 2015;31(2):193-5.

  12. Farajollahi A, Williams GM, Condon GC, Kesavaraju B, Unlu I, Gaugler R. Assessment of a Direct Application of Two Bacillus thuringiensis israelensis Formulations for Immediate and Residual Control of Aedes albopictus. Journal of the American Mosquito Control Association. 2013;29(4):385-8.

  13. Ritchie SA, Rapley LP, Benjamin S. Bacillus thuringiensis var.israelensis (Bti) Provides Residual Control of Aedes aegypti in Small Containers. Am J Trop Med Hyg. 2010;82(6):1053-9.

  14. Setha T, Chantha N, Socheat D. Efficacy of Bacillus thuringiensis israelensis, VectoBac WG and DT, formulations against dengue mosquito vectors in cement potable water jars in Cambodia. Southeast Asian J Trop Med Public Health. 2007;38(2):261-8.

  15. Gato R, Díaz M, Bruzón RY, Menéndez Z, González A, Hernández Y,et al. Estudio de resistencia de Aedes aegypti a Bacillus thuringiensis var. israelensis. Rev Cubana Med Trop. 2008;60(1):74-7.

  16. Menéndez Z, Rodríguez J, Gato R, Companioni A, Díaz M, Bruzón RY. Susceptibility of Aedes aegypti (L.) strains from Havana to a Bacillus thuringiensis var. israelensis. Rev Cuba Med Trop. 2012;64(3):324-9.

  17. Li Y, Xu J, Zhong D, Zhang H, Yang W, Zhou G, et al. Evidence for multipleinsecticide resistance in urban Aedes albopictus populations in southern China. Parasites & Vectors. 2018;11(1):4.

  18. Ben-Dov E. Bacillus thuringiensis subsp. israelensis and Its Dipteran-Specific Toxins. Toxins. 2014;6(4):1222-43.

  19. Harwood JF, Farooq M, Turnwall BT, Richardson AG. Evaluating Liquid and Granular Bacillus thuringiensis var. israelensis Broadcast Applications for Controlling Vectors of Dengue and Chikungunya Viruses in Artificial Containers and Tree Holes. Journal of Medical Entomology. 2015;52(4):663-71.




2020     |     www.medigraphic.com